The Experts below are selected from a list of 279 Experts worldwide ranked by ideXlab platform
Tetsuo Hayashi - One of the best experts on this subject based on the ideXlab platform.
-
Metastatic tumor of spermatic cord with elevation of serum human Chorionic Gonadotropin Beta-subunit
The Japanese Journal of Urology, 2005Co-Authors: Soichiro Yoshida, Tetsuo Hayashi, Atsushi Yoshinaga, Nobuyuki Ishii, Rena Ohno, Toru Watanabe, Toshiya Terao, Takumi YamadaAbstract:: A 62-year-old man was presented with a firm mass in right scrotum. Serum LDH and AFP were within normal range, but hCG-Beta was elevated (2.3 ng/ml). Under the diagnosis of right testicular tumor, he underwent right radical orchiectomy. The specimen was a spermatic cord tumor with poorly differentiated adenocarcinoma. hCG-Beta was still elevated postoperatively and gastric fiber revealed adenocarcinoma of the stomach. Histochemical staining for hCG-Beta was positive in both tumor of the spermatic cord and stomach. Finally the tumor was diagnosed as metastatic tumor of spermatic cord from gastric cancer, causing the elevation of hCG-Beta.
-
Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer
International Journal of Urology, 2005Co-Authors: Atsushi Yoshinaga, Tetsuo Hayashi, Nobuyuki Ishii, Rena Ohno, Toru Watanabe, Takumi YamadaAbstract:: Although the association between dermatomyositis and cancer is well recognized, there have been a limited number of reports of dermatomyositis associated with testicular cancer. We report the case of a 31-year-old man who was diagnosed with dermatomyositis. Because the patient's serum levels of alpha-fetoprotein and human Chorionic Gonadotropin Beta subunit were elevated, the patient was referred to our department. Physical examination revealed an induration (2 cm x 2 cm) in the left testis and the patient was diagnosed with stage IIIB left testicular cancer. A left high orchidectomy was then performed, and pathological examination revealed embryonal carcinoma. The patient was started on a systemic chemotherapeutic (etoposide, ifosfamide and cisplatin; VIP) regimen. After the third chemotherapy session, metastases had completely disappeared, the serum levels of alpha-fetoprotein and human Chorionic Gonadotropin Beta subunit had normalized and the dermatomyositis symptoms had improved. Cancer is known to be a trigger of dermatomyositis. This case illustrates the importance of palpation of the testes in young patients with dermatomyositis.
-
Suppression of spermatogenesis in ipsilateral and contralateral testicular tissues in patients with seminoma by human Chorionic Gonadotropin Beta subunit
Urology, 2001Co-Authors: Tetsuo Hayashi, Gaku Arai, Nobuhiko Hyochi, Masahito Suzuki, Hitoshi Masuda, Satoru Kawakami, Tetsuo Okuno, Kazuhiro Ishizaka, Yukio Kageyama, Kazunori KiharaAbstract:Objectives. The pathologic complexity of the testicular tumor makes it difficult to demonstrate exactly the relationship between the impaired spermatogenesis in patients with a testicular tumor and the serum level of the human Chorionic Gonadotropin Beta subunit (Beta-hCG). Therefore, we performed quantitative evaluation of spermatogenesis in ipsilateral and contralateral testicular tissues of seminoma to simplify the relation pathologically and endocrinologically and to demonstrate the exact correlation between spermatogenesis and serum Beta-hCG levels. Methods. Fifty-three biopsy specimens from ipsilateral and contralateral testicular tissues of seminoma were analyzed histologically. The quantitative evaluation of spermatogenesis was performed by the mean Johnsen’s score count (MJSC). Beta-hCG expression in seminoma was examined immunohistochemically. Serum Beta-hCG, testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone levels were analyzed before orchiectomy. Results. A significant linear relationship (r = −0.82; P
-
suppression of spermatogenesis in ipsilateral and contralateral testicular tissues in patients with seminoma by human Chorionic Gonadotropin Beta subunit
Urology, 2001Co-Authors: Tetsuo Hayashi, Gaku Arai, Nobuhiko Hyochi, Masahito Suzuki, Hitoshi Masuda, Satoru Kawakami, Tetsuo Okuno, Kazuhiro Ishizaka, Yukio Kageyama, Kazunori KiharaAbstract:Objectives. The pathologic complexity of the testicular tumor makes it difficult to demonstrate exactly the relationship between the impaired spermatogenesis in patients with a testicular tumor and the serum level of the human Chorionic Gonadotropin Beta subunit (Beta-hCG). Therefore, we performed quantitative evaluation of spermatogenesis in ipsilateral and contralateral testicular tissues of seminoma to simplify the relation pathologically and endocrinologically and to demonstrate the exact correlation between spermatogenesis and serum Beta-hCG levels. Methods. Fifty-three biopsy specimens from ipsilateral and contralateral testicular tissues of seminoma were analyzed histologically. The quantitative evaluation of spermatogenesis was performed by the mean Johnsen’s score count (MJSC). Beta-hCG expression in seminoma was examined immunohistochemically. Serum Beta-hCG, testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone levels were analyzed before orchiectomy. Results. A significant linear relationship (r = −0.82; P <0.005) was found between the serum level of Beta-hCG and the MJSC in contralateral testicular tissues but not in ipsilateral ones, although the suppression of spermatogenesis was observed in both sides without suppression of luteinizing hormone and/or follicle-stimulating hormone production. Conclusions. A clearcut fall in the MJSC with an associated rise in the serum level of Beta-hCG was demonstrated in the contralateral testicular tissues but not in the ipsilateral ones of seminoma. It seems most likely that serum Beta-hCG suppresses spermatogenesis in both ipsilateral and contralateral testicular tissues without the suppression occurring through the hypothalamus-pituitary-gonadal system, and also that some less well recognized factors affect spermatogenesis, making the relation between serum Beta-hCG and MJSC obscure in ipsilateral testicular tissues.
Kazunori Kihara - One of the best experts on this subject based on the ideXlab platform.
-
Suppression of spermatogenesis in ipsilateral and contralateral testicular tissues in patients with seminoma by human Chorionic Gonadotropin Beta subunit
Urology, 2001Co-Authors: Tetsuo Hayashi, Gaku Arai, Nobuhiko Hyochi, Masahito Suzuki, Hitoshi Masuda, Satoru Kawakami, Tetsuo Okuno, Kazuhiro Ishizaka, Yukio Kageyama, Kazunori KiharaAbstract:Objectives. The pathologic complexity of the testicular tumor makes it difficult to demonstrate exactly the relationship between the impaired spermatogenesis in patients with a testicular tumor and the serum level of the human Chorionic Gonadotropin Beta subunit (Beta-hCG). Therefore, we performed quantitative evaluation of spermatogenesis in ipsilateral and contralateral testicular tissues of seminoma to simplify the relation pathologically and endocrinologically and to demonstrate the exact correlation between spermatogenesis and serum Beta-hCG levels. Methods. Fifty-three biopsy specimens from ipsilateral and contralateral testicular tissues of seminoma were analyzed histologically. The quantitative evaluation of spermatogenesis was performed by the mean Johnsen’s score count (MJSC). Beta-hCG expression in seminoma was examined immunohistochemically. Serum Beta-hCG, testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone levels were analyzed before orchiectomy. Results. A significant linear relationship (r = −0.82; P
-
suppression of spermatogenesis in ipsilateral and contralateral testicular tissues in patients with seminoma by human Chorionic Gonadotropin Beta subunit
Urology, 2001Co-Authors: Tetsuo Hayashi, Gaku Arai, Nobuhiko Hyochi, Masahito Suzuki, Hitoshi Masuda, Satoru Kawakami, Tetsuo Okuno, Kazuhiro Ishizaka, Yukio Kageyama, Kazunori KiharaAbstract:Objectives. The pathologic complexity of the testicular tumor makes it difficult to demonstrate exactly the relationship between the impaired spermatogenesis in patients with a testicular tumor and the serum level of the human Chorionic Gonadotropin Beta subunit (Beta-hCG). Therefore, we performed quantitative evaluation of spermatogenesis in ipsilateral and contralateral testicular tissues of seminoma to simplify the relation pathologically and endocrinologically and to demonstrate the exact correlation between spermatogenesis and serum Beta-hCG levels. Methods. Fifty-three biopsy specimens from ipsilateral and contralateral testicular tissues of seminoma were analyzed histologically. The quantitative evaluation of spermatogenesis was performed by the mean Johnsen’s score count (MJSC). Beta-hCG expression in seminoma was examined immunohistochemically. Serum Beta-hCG, testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone levels were analyzed before orchiectomy. Results. A significant linear relationship (r = −0.82; P <0.005) was found between the serum level of Beta-hCG and the MJSC in contralateral testicular tissues but not in ipsilateral ones, although the suppression of spermatogenesis was observed in both sides without suppression of luteinizing hormone and/or follicle-stimulating hormone production. Conclusions. A clearcut fall in the MJSC with an associated rise in the serum level of Beta-hCG was demonstrated in the contralateral testicular tissues but not in the ipsilateral ones of seminoma. It seems most likely that serum Beta-hCG suppresses spermatogenesis in both ipsilateral and contralateral testicular tissues without the suppression occurring through the hypothalamus-pituitary-gonadal system, and also that some less well recognized factors affect spermatogenesis, making the relation between serum Beta-hCG and MJSC obscure in ipsilateral testicular tissues.
Anna Jankowska - One of the best experts on this subject based on the ideXlab platform.
-
Human Chorionic Gonadotropin-Beta in endometrium cancer tissue.
European Journal of Gynaecological Oncology, 2020Co-Authors: Ewa Nowak-markwitz, Anna Szczerba, Anna Jankowska, Miroslaw AndrusiewiczAbstract:PURPOSE: Determination of the correlation between expression of human Chorionic Gonadotropin mRNA and serum free hCGb immunoreactivity in endometrial cancer tissue. METHODS: The study included 56 patients with endometrial carcinoma Stages IB-III. The expression of mRNA hCGBeta was determined by the RT PCR method in 18 cases of cancerous and precancerous tissues. The serum-free hCGBeta immunoreactivity was analyzed by sequential immunometric assay in all patients. RESULTS: In 15 study specimens of endometrial carcinoma tissue mRNA of hCGBeta was detected. Also in endometrial atypical hyperplasia, expression of hCGBeta was found. Noncancerous tissue demonstrated lack of the hCGBeta transcript. The serum immunoreactivity in the endometrial cancer group was detectable in 86% of cases. There were no significant differences between FIGO stages and grading. CONCLUSION: The results of the present study confirmed the presence of active genes of hCGBeta in endometrial cancer tissue, even in precancerous changes. The serum immunoreactivity of free hCGBeta is a less common feature and is not linked with tumor stage or grade in endometrial cancer patients.
-
Regulation of human Chorionic Gonadotropin Beta subunit expression in ovarian cancer
BMC Cancer, 2019Co-Authors: Aleksandra Śliwa, Marta Kubiczak, Anna Szczerba, Grzegorz P. Walkowiak, Ewa Nowak-markwitz, Beata Burczynska, Stephen A. Butler, Ray Kruse Iles, Piotr Białas, Anna JankowskaAbstract:Expression of human Chorionic Gonadotropin Beta subunit by cancers is extensively documented, yet regulation of the multiple genes that can code for this protein is poorly understood. The aim of the study was to examine the mechanisms regulating CGB gene expression in ovarian cancer. Expression of CGB genes and SP1, SP3, TFAP2A transcription factor genes was evaluated by RT-qPCR. The methylation status of CGB genes promoter regions was examined by methylation-specific PCR. mRNA arising from multiple CGB genes was detected in both ovarian control and malignant tissues. However, expression of CGB3–9 genes was shown to be significantly higher in malignant than healthy ovarian tissues. CGB1 and CGB2 transcripts were shown to be present in 20% of ovarian cancers, but were not detected in any of the control samples. Malignant tissues were characterized by DNA demethylation of CGB promoter regions. In ovarian cancer CGB expression positively correlated with TFAP2A transcripts level and expression of TFAP2A transcription factor was significantly higher in cancer than in control tissues. In contrast SP3 expression level was significantly lower in ovarian tumours than in control ovarian tissue. In ovarian cancers increased expression of human Chorionic Gonadotropin Beta subunit is associated with demethylation of CGB promoter regions. CGB3–9 expression level strongly correlates with expression of the TFAP2A transcription factor. Presence of mRNA arising from CGB1 and CGB2 genes appears to be a unique feature of a subset of ovarian cancers.
-
human Chorionic Gonadotropin Beta subunit genes cgb1 and cgb2 are transcriptionally active in ovarian cancer
International Journal of Molecular Sciences, 2013Co-Authors: Marta Kubiczak, Grzegorz P. Walkowiak, Ewa Nowakmarkwitz, Anna JankowskaAbstract:Human Chorionic Gonadotropin Beta subunit (CGB) is a marker of pregnancy as well as trophoblastic and nontrophoblastic tumors. CGB is encoded by a cluster of six genes, of which type II genes (CGB3/9, 5 and 8) have been shown to be upregulated in relation to type I genes (CGB6/7) in both placentas and tumors. Recent studies revealed that CGB1 and CGB2, originally considered as pseudogenes, might also be active, however, the protein products of these genes have not yet been identified. Our study demonstrates the presence of CGB1 and CGB2 transcripts in ovarian carcinomas. While CGB1 and CGB2 gene activation was not detected in normal ovaries lacking cancerous development, our study demonstrates the presence of CGB1 and CGB2 transcripts in 41% of analyzed ovarian cancer cases.
-
CGB and GNRH1 expression analysis as a method of tumor cells metastatic spread detection in patients with gynecological malignances.
Journal of Translational Medicine, 2011Co-Authors: Miroslaw Andrusiewicz, Anna Szczerba, Ewa Nowak-markwitz, Maria Wołuń-cholewa, Wojciech Warchoł, Emilia Gąsiorowska, Krystyna Adamska, Anna JankowskaAbstract:Background Metastasis is a common feature of many advanced stage cancers and metastatic spread is thought to be responsible for cancer progression. Most cancer cells are localized in the primary tumor and only a small population of circulating tumor cells (CTC) has metastatic potential. CTC amount reflects the aggressiveness of tumors, therefore their detection can be used to determine the prognosis and treatment of cancer patients. The aim of this study was to evaluate human Chorionic Gonadotropin Beta subunit (CGB) and gonadoliberin type 1 (GNRH1) expression as markers of tumor cells circulating in peripheral blood of gynecological cancer patients, indicating the metastatic spread of tumor.
-
coexpression of human Chorionic Gonadotropin Beta subunit and its receptor in nontrophoblastic gynecological cancer
International Journal of Gynecological Cancer, 2008Co-Authors: Anna Jankowska, Miroslaw Andrusiewicz, Ewa Nowakmarkwitz, J Grabowski, Jerzy B WarcholAbstract:A considerable number of biochemical and physiologic studies evaluate the roles of Gonadotropins in carcinogenesis. Latest reports show that human Chorionic Gonadotropin (hCG), and especially its Beta subunit, are secreted by a variety of malignant tumors of different origin. However, the mechanism of hCG action and its role in tumor development is not known yet. This study, with the help of reverse transcription-polymerase chain reaction and immunohistochemistry, is an attempt to document the molecular presence of the hCGβ and luteinizing hormone/hCG receptor (LH/hCGR) in the ovarian, endometrial, and uterine cervix cancer tissues. The LH/hCGR, coexpressed with hCGβ, may act as a potential mediator of hCG action in nontrophoblastic gynecological cancers
Jerzy B Warchol - One of the best experts on this subject based on the ideXlab platform.
-
coexpression of human Chorionic Gonadotropin Beta subunit and its receptor in nontrophoblastic gynecological cancer
International Journal of Gynecological Cancer, 2008Co-Authors: Anna Jankowska, Miroslaw Andrusiewicz, Ewa Nowakmarkwitz, J Grabowski, Jerzy B WarcholAbstract:A considerable number of biochemical and physiologic studies evaluate the roles of Gonadotropins in carcinogenesis. Latest reports show that human Chorionic Gonadotropin (hCG), and especially its Beta subunit, are secreted by a variety of malignant tumors of different origin. However, the mechanism of hCG action and its role in tumor development is not known yet. This study, with the help of reverse transcription-polymerase chain reaction and immunohistochemistry, is an attempt to document the molecular presence of the hCGβ and luteinizing hormone/hCG receptor (LH/hCGR) in the ovarian, endometrial, and uterine cervix cancer tissues. The LH/hCGR, coexpressed with hCGβ, may act as a potential mediator of hCG action in nontrophoblastic gynecological cancers
-
reduction of human Chorionic Gonadotropin Beta subunit expression by modified u1 snrna caused apoptosis in cervical cancer cells
Molecular Cancer, 2008Co-Authors: Anna Jankowska, Anna Szczerba, Beata Burczynska, Samuel I Gunderson, Miroslaw Andrusiewicz, Artur Jarmolowski, Ewa Nowakmarkwitz, Jerzy B WarcholAbstract:Secretion of human Chorionic Gonadotropin, especially its Beta subunit by malignant trophoblastic tumors and varieties of tumors of different origin is now well documented; however the role of hCG in tumorogenesis is still unknown. This study documents the molecular presence of human Chorionic Gonadotropin Beta subunit in uterine cervix cancer tissues and investigates a novel technique to reduce hCGβ levels based on expression of a modified U1 snRNA as a method to study the hormone's role in biology of human cervical cancer cells cultured in vitro. The property of U1 snRNA to block the accumulation of specific RNA transcript when it binds to its donor sequence within the 3' terminal exon was used. The first 10 nucleotides of the human U1 snRNA gene, which normally binds to the 5'ss in pre-mRNA were replaced by a sequence complementary to a 10-nt segment in the terminal exon of the hCGβ mRNA. Three different 5' end-mutated U1 snRNA expression plasmids were tested, each targeting a different sequence in the hCGβ mRNA, and we found each one blocked the expression of hCGβ in HeLa cells, a cervix carcinoma cell line, as shown by immunohistochemistry and qRT-PCR. Reduction of hCGβ levels resulted in a significantly increased apoptosis rate with almost 90% of cells transfected with modified anti-hCGβ U1 snRNAs showing morphological changes characteristic of the apoptotic process. These data suggest that human Chorionic Gonadotropin Beta subunit may act as a tumor growth-stimulating factor.
-
Localization of human Chorionic Gonadotropin Beta subunit transcripts in ovarian cancer tissue
Folia Histochemica Et Cytobiologica, 2004Co-Authors: Ewa Nowak-markwitz, Anna Szczerba, Anna Jankowska, Miroslaw Andrusiewicz, Jerzy B WarcholAbstract:Recent studies demonstrated that besides placenta and malignant trophoblastic tumors, hCG and especially its Beta-subunit is secreted by a varieties of tumors of different origin. The aim of the present investigation was to determine the expression pattern of human Chorionic Gonadotropin gene in ovarian cancer tissue. The study included 8 patients with epithelial ovarian carcinoma. The expression and distribution of hCGBeta mRNA was assessed by in situ RT-PCR method. The semi-quantitative assessment was performed using computer image analysis. Transformation of the images into the pseudocolour scale showed a clear difference in fluorescence intensity among individual cancer cells. The intensity of ISRT-PCR products corresponding with expression level of hCGBeta demonstrated that its production by individual cancer cells is different. In all studied specimens of the ovarian carcinoma tissue, cancer cells characterized by the presence of active hCGBeta gene were found, whereas noncancerous tissue demonstrated lack of the gene expression. Thus, the study clearly shows that the expression of hCGBeta is the feature of ovarian cancer tissue.
Gaku Arai - One of the best experts on this subject based on the ideXlab platform.
-
Suppression of spermatogenesis in ipsilateral and contralateral testicular tissues in patients with seminoma by human Chorionic Gonadotropin Beta subunit
Urology, 2001Co-Authors: Tetsuo Hayashi, Gaku Arai, Nobuhiko Hyochi, Masahito Suzuki, Hitoshi Masuda, Satoru Kawakami, Tetsuo Okuno, Kazuhiro Ishizaka, Yukio Kageyama, Kazunori KiharaAbstract:Objectives. The pathologic complexity of the testicular tumor makes it difficult to demonstrate exactly the relationship between the impaired spermatogenesis in patients with a testicular tumor and the serum level of the human Chorionic Gonadotropin Beta subunit (Beta-hCG). Therefore, we performed quantitative evaluation of spermatogenesis in ipsilateral and contralateral testicular tissues of seminoma to simplify the relation pathologically and endocrinologically and to demonstrate the exact correlation between spermatogenesis and serum Beta-hCG levels. Methods. Fifty-three biopsy specimens from ipsilateral and contralateral testicular tissues of seminoma were analyzed histologically. The quantitative evaluation of spermatogenesis was performed by the mean Johnsen’s score count (MJSC). Beta-hCG expression in seminoma was examined immunohistochemically. Serum Beta-hCG, testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone levels were analyzed before orchiectomy. Results. A significant linear relationship (r = −0.82; P
-
suppression of spermatogenesis in ipsilateral and contralateral testicular tissues in patients with seminoma by human Chorionic Gonadotropin Beta subunit
Urology, 2001Co-Authors: Tetsuo Hayashi, Gaku Arai, Nobuhiko Hyochi, Masahito Suzuki, Hitoshi Masuda, Satoru Kawakami, Tetsuo Okuno, Kazuhiro Ishizaka, Yukio Kageyama, Kazunori KiharaAbstract:Objectives. The pathologic complexity of the testicular tumor makes it difficult to demonstrate exactly the relationship between the impaired spermatogenesis in patients with a testicular tumor and the serum level of the human Chorionic Gonadotropin Beta subunit (Beta-hCG). Therefore, we performed quantitative evaluation of spermatogenesis in ipsilateral and contralateral testicular tissues of seminoma to simplify the relation pathologically and endocrinologically and to demonstrate the exact correlation between spermatogenesis and serum Beta-hCG levels. Methods. Fifty-three biopsy specimens from ipsilateral and contralateral testicular tissues of seminoma were analyzed histologically. The quantitative evaluation of spermatogenesis was performed by the mean Johnsen’s score count (MJSC). Beta-hCG expression in seminoma was examined immunohistochemically. Serum Beta-hCG, testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone levels were analyzed before orchiectomy. Results. A significant linear relationship (r = −0.82; P <0.005) was found between the serum level of Beta-hCG and the MJSC in contralateral testicular tissues but not in ipsilateral ones, although the suppression of spermatogenesis was observed in both sides without suppression of luteinizing hormone and/or follicle-stimulating hormone production. Conclusions. A clearcut fall in the MJSC with an associated rise in the serum level of Beta-hCG was demonstrated in the contralateral testicular tissues but not in the ipsilateral ones of seminoma. It seems most likely that serum Beta-hCG suppresses spermatogenesis in both ipsilateral and contralateral testicular tissues without the suppression occurring through the hypothalamus-pituitary-gonadal system, and also that some less well recognized factors affect spermatogenesis, making the relation between serum Beta-hCG and MJSC obscure in ipsilateral testicular tissues.